Under the proposed deal, CD&R would acquire a 50% controlling interest in Opella, while Sanofi would retain a substantial stake, positioning itself as a key player in the company’s future ...

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share ...

Bpifrance is expected to participate as a minority shareholder with a c.2% stake in Opella, with Sanofi remaining a significant shareholder. The terms of the transaction remain unchanged from ...

Sanofi is now in exclusive talks with private equity company Clayton Dubilier & Rice over the sale of a controlling stake in its consumer health business Opella, as the French government seeks to ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

The debt package for the unit, which is called Opella, was one of the most hotly anticipated financing deals to come to market this year in Europe and the US. It included €5.2 billion-equivalent ...

The debt package for the unit, which is called Opella, was one of the most hotly ... to CD&R last year so the firm could buy part of Sanofi’s consumer arm. But they had to keep the debt on ...